Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & ExpoBusiness Wire • 19 days ago
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in...
Share to Feed
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 30, 2024, the Companys Board of Directors approved...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Arrowhead Pharmaceuticals Inc (ARWR), where a total of 9,321 contracts have traded so far...
This is a Bearish indicator signaling ARWR's price could decline from here. Traders may explore shorting the stock or put options...
This indicator may be signaling that ARWR's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
This price move could indicate a change in the trend, and may be a sell signal for investors...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a double-blinded, placebo-controlled, dose-escalating study (NCT06138743) to evaluate...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen's 44th Annual Health Care Conference March 6, 2024 Type...
This price move could indicate a change in the trend, and may be a buy signal for investors...